Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007307 | 0.90 | L3MBTL1 (0.46) | L3MBTL1CASP1HSD17B10CYP3A4ABCB1 | |
| SCHEMBL3005304 | 0.89 | L3MBTL1 (0.48) | L3MBTL1CASP1HSD17B10CYP3A4ABCB1 | |
| SCHEMBL16139141 | 0.82 | CCR1 (0.37) | CCR1 | |
| SCHEMBL13243815 | 0.81 | NFE2L2 (0.41) | L3MBTL1CASP1HSD17B10CYP3A4NFE2L2 | |
| SCHEMBL3007175 | 0.80 | MAPT (0.41) | CCR1KMT2AMAPTMEN1TSHR | |
| SCHEMBL3015781 | 0.80 | NFE2L2 (0.40) | L3MBTL1CASP1HSD17B10CYP3A4NFE2L2 | |
| SCHEMBL3009832 | 0.80 | CYP3A4 (0.64) | CYP3A4ABCB1CYP3A5CYP2C19CYP1A2 | |
| SCHEMBL29580483 | 0.79 | CCR1 (0.41) | CCR1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL3001061 | 0.78 | NFE2L2 (0.39) | L3MBTL1CASP1HSD17B10CYP3A4NFE2L2 | |
| SCHEMBL3012721 | 0.78 | HDAC3 (0.42) | L3MBTL1CASP1HSD17B10CYP3A4NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2023-08-17 | — | — | US | disclosed |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-10-14 | — | — | US | disclosed |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-10-14 | — | — | US | disclosed |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-03-04 | — | — | US | disclosed |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2021-03-04 | — | — | US | disclosed |
| US-9227918-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS (CA) | 2016-01-05 | — | — | US | disclosed |
| US-9227918-B2 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS (CA) | 2016-01-05 | — | — | US | disclosed |
| US-20140296335-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296335-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ACQUIOM AGENCY SERVICES, LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2170050-B1 | Short acting phenylalkylamine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC (CA) | 2014-06-18 | — | — | EP | disclosed |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2010-07-29 | — | — | US | disclosed |
| EP-2170050-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | Milestone Pharmaceuticals Inc. (CA) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156820-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115543-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20220142963-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20230255923-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20210315855-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20210059972-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20140296335-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20100190852-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | L3MBTL1 3547/4885CASP1 2264/4885HSD17B10 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.